Regenerating skeletal muscle in the face of aging and disease

American Journal of Physical Medicine and Rehabilitation

Volumn 93, Issue 11, 2014, Pages S88-S96

  Jasuja, Ravi ^a   Le Brasseur, Nathan K ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Cachexia; Frailty; Myostatin; Physical function; Sarcopenia; Selective androgen receptor modulators; Troponin

Indexed keywords

ESTROGEN; MYOSTATIN; TESTOSTERONE;

AGED; AGING; ANTAGONISTS AND INHIBITORS; CACHEXIA; DRUG EFFECTS; EXERCISE; FEMALE; FRAIL ELDERLY; HORMONE SUBSTITUTION; HUMAN; MALE; MULTIMODALITY CANCER THERAPY; MUSCLE CONTRACTION; MUSCLE STRENGTH; MUSCLE WEAKNESS; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SARCOPENIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; CACHEXIA; COMBINED MODALITY THERAPY; ESTROGENS; EXERCISE; FEMALE; FRAIL ELDERLY; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MUSCLE CONTRACTION; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYOSTATIN; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SARCOPENIA; SEVERITY OF ILLNESS INDEX; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84914812786     PISSN: 08949115     EISSN: 15377385     Source Type: Journal    
DOI: 10.1097/PHM.0000000000000118     Document Type: Article

References (70)

1. Rosenberg IH: Sarcopenia: Origins and clinical relevance. J Nutr 1997;127:990S-1S
2. Fielding RA, Vellas B, Evans WJ, et al: Sarcopenia: An undiagnosed condition in older adults. Current consensus definition: Prevalence, etiology, and consequences. International Working Group on Sarcopenia. J AmMed Dir Assoc 2011;12:249-56
3. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al: Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in older people. Age Ageing 2010;39:412-23
4. Muscaritoli M, Anker SD, Argiles J, et al: Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) Bcachexia-Anorexia in chronic wasting diseases[and Bnutrition in geriatrics. J Clin Nutr 2010;29:154-9
5. Fearon K, Strasser F, Anker SD, et al: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol 2011;12:489-95
6. Fried LP, Tangen CM, Walston J, et al: Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146-56
7. Baumgartner RN, Koehler KM, Gallagher D, et al: Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998;147:755-63
8. Doherty TJ: Invited review: Aging and sarcopenia. J Appl Physiol 2003;95:1717-27
9. Lenk K, Schuler G, Adams V: Skeletal muscle wasting in cachexia and sarcopenia: Molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle 2010;1:9-21
10. Marcell TJ: Sarcopenia: Causes, consequences, and preventions. J Gerontol A Biol Sci Med Sci 2003;58:M911-6
11. Janssen I, Heymsfield SB, Ross R: Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 2002;50:889-96
12. Fuller-Thomson E, Yu B, Nuru-Jeter A, et al: Basic ADL disability and functional limitation rates among older Americans from 2000-2005: The end of the decline? J Gerontol A Biol Sci Med Sci 2009;64:1333-6
13. Tinetti ME, Speechley M, Ginter SF: Risk factors for falls among elderly persons living in the community. N Engl J Med 1988;319:1701-7
14. Guralnik JM, Ferrucci L, Simonsick EM, et al: Lowerextremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl J Med 1995;332:556-61
15. Studenski S, Perera S, Wallace D, et al: Physical performance measures in the clinical setting. J AmGeriatr Soc 2003;51:314-22
16. Hardy SE, Perera S, Roumani YF, et al: Improvement in usual gait speed predicts better survival in older adults. J Am Geriatr Soc 2007;55:1727-34
17. Newman AB, Kupelian V, Visser M, et al: Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. J Gerontol A Biol Sci Med Sci 2006;61:72-7
18. Newman AB, Simonsick EM, Naydeck BL, et al: Association of long-distance corridor walk performance with mortality, cardiovascular disease, mobility limitation, and disability. JAMA 2006;295:2018-26
19. Kohrt WM, Kirwan JP, Staten MA, et al: Insulin resistance in aging is related to abdominal obesity. Diabetes 1993;42:273-81
20. Basu R, Breda E, Oberg AL, et al: Mechanisms of the age-Associated deterioration in glucose tolerance: Contribution of alterations in insulin secretion, action, and clearance. Diabetes 2003;52:1738-48
21. Akasaki Y, Ouchi N, Izumiya Y, et al: Glycolytic fasttwitch muscle fiber restoration counters adverse age-related changes in body composition and metabolism. Aging Cell 2013;13:80-91
22. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA, U. S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011
23. Makary MA, Segev DL, Pronovost PJ, et al: Frailty as a predictor of surgical outcomes in older patients. J Am Coll Surg 2010;210:901-8
24. Bandeen-Roche K, Xue QL, Ferrucci L, et al: Phenotype of frailty: Characterization in the women's health and aging studies. J Gerontol A Biol Sci Med Sci 2006;61:262-6
25. Von Haehling S, Anker SD: Cachexia as a major underestimated and unmet medical need: Facts and numbers. J Cachexia Sarcopenia Muscle 2010;1:1-5
26. Tisdale MJ: Cachexia in cancer patients. Nat Rev Cancer 2002;2:862-71
27. Von Haehling S, Lainscak M, Springer J, et al: Cardiac cachexia: A systematic overview. Pharmacol Ther 2009;121:227-52
28. Congleton J: The pulmonary cachexia syndrome: Aspects of energy balance. Proc Nutr Soc 1999;58:321-8
29. Roberts BM, Ahn B, Smuder AJ, et al: Diaphragm and ventilatory dysfunction during cancer cachexia. FASEB J 2013;27:2600-10
30. Fouladiun M, Korner U, Gunnebo L, et al: Daily physicalrest activities in relation to nutritional state, metabolism, and quality of life in cancer patients with progressive cachexia. Clin Cancer Res 2007;13:6379-85
31. McPherron AC, Lawler AM, Lee SJ: Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997;387:83-90
32. Langley B, Thomas M, Bishop A, et al: Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J Biol Chem 2002;277:49831-40
33. Yang W, Zhang Y, Li Y, et al: Myostatin induces cyclin D1 degradation to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3 beta pathway and is antagonized by insulin-like growth factor 1. J Biol Chem 2007;282:3799-808
34. Sartori R, Milan G, Patron M, et al: Smad2 and 3 transcription factors control muscle mass in adulthood. Am J Physiol Cell Physiol 2009;296:C1248-57
35. Trendelenburg AU, Meyer A, Rohner D, et al: Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol 2009;296:C1258-70
36. Zimmers TA, Davies MV, Koniaris LG, et al: Induction of cachexia in mice by systemically administered myostatin. Science 2002;296:1486-8
37. Clop A, Marcq F, Takeda H, et al: A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat Genet 2006;38:813-8
38. Mosher DS, Quignon P, Bustamante CD, et al: A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet 2007;3:e79
39. McPherron AC, Lee SJ: Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 1997;94:12457-61
40. Schuelke M, Wagner KR, Stolz LE, et al: Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004;350:2682-8
41. White TA, Le Brasseur NK: Myostatin and sarcopenia: Challenges and opportunities. Gerontology 2014; DOI: 10.1159/000356740 PMID: 24457615 (Epub ahead of print)
42. Le Brasseur NK, Schelhorn TM, Bernardo BL, et al: Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice. J Gerontol A Biol Sci Med Sci 2009;64:940-8
43. Zhou X, Wang JL, Lu J, et al: Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010;142:531-43
44. Bogdanovich S, Krag TOB, Barton ER, et al: Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002;420:418-21
45. Wagner KR, Liu X, Chang X, et al: Muscle regeneration in the prolonged absence of myostatin. Proc Natl Acad Sci USA 2005;102:2519-24
46. Attie KM, Borgstein NG, Yang Y, et al: A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve 2013;47:416-23
47. Wilkes JJ, Lloyd DJ, Gekakis N: Loss-of-function mutation in myostatin reduces tumor necrosis factor alpha production and protects liver against obesityinduced insulin resistance. Diabetes 2009;58:1133-43
48. Morissette MR, Stricker JC, Rosenberg MA, et al: Effects of myostatin deletion in aging mice. Aging Cell 2009;8:573-83
49. Tu P, Bhasin S, Hruz PW, et al: Genetic disruption of myostatin reduces the development of proatherogenic dyslipidemia and atherogenic lesions in Ldlr null mice. Diabetes 2009;58:1739-48
50. Lebrasseur NK: Building muscle, browning fat and preventing obesity by inhibiting myostatin. Diabetologia 2012;55:13-7
51. Le Brasseur NK, Walsh K, Arany Z: Metabolic benefits of resistance training and fast glycolytic skeletal muscle. Am J Physiol Endocrinol Metab 2011;300:E3-10
52. Lee SJ: Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. PLoS One 2007;2:e789
53. Bhasin S, Woodhouse L, Casaburi R, et al: Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001;281:E1172-81
54. Bhasin S, Woodhouse L, Casaburi R, et al: Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 2005;90:678-88
55. Woodhouse LJ, Reisz-Porszasz S, Javanbakht M, et al: Development of models to predict anabolic response to testosterone administration in healthy young men. Am J Physiol Endocrinol Metab 2003;284:E1009-17
56. Storer TW, Magliano L, Woodhouse L, et al: Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab 2003;88:1478-85
57. Bhasin S, Storer TW, Berman N, et al: The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996;335:1-7
58. Bhasin S, Storer TW, Berman N, et al: Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997;82:407-13
59. Casaburi R, Bhasin S, Cosentino L, et al: Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:870-8
60. Johansen KL, Mulligan K, Schambelan M: Anabolic effects of nandrolone decanoate in patients receiving dialysis: A randomized controlled trial. JAMA 1999;281:1275-81
61. Calof OM, Singh AB, Lee ML, et al: Adverse events associated with testosterone replacement in middleaged and older men: A meta-Analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005;60:1451-7
62. Heinlein CA, Chang C: Androgen receptor (AR) coregulators: An overview. Endocr Rev 2002;23:175-200
63. Russell DW, Wilson JD: Steroid 5 alpha-reductase: Two genes/two enzymes. Annu Rev Biochem 1994;63:25-61
64. Narayanan R, Coss CC, Yepuru M, et al: Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol 2008;22:2448-65
65. Allan GF, Tannenbaum P, Sbriscia T, et al: A selective androgen receptor modulator with minimal prostate hypertrophic activity enhances lean body mass in male rats and stimulates sexual behavior in female rats. Endocrine 2007;32:41-51
66. Ostrowski J, Kuhns JE, Lupisella JA, et al: Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: Potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology 2007;148:4-12
67. Schmidt A, Kimmel DB, Bai C, et al: Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology. J Biol Chem 2010;285:17054-64
68. Dalton JT, Barnette KG, Bohl CE, et al: The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: Results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle 2011;2:153-61
69. Russell AJ, Hartman JJ, Hinken AC, et al: Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med 2012;18:452-5
70. Shefner J, Cedarbaum JM, Cudkowicz ME, et al: Safety, tolerability and pharmacodynamics of a skeletalmuscle activator in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2012;13:430-8